Literature DB >> 8951778

The diagnostic criteria of polycythaemia rubra vera.

T C Pearson1, M Messinezy.   

Abstract

There is no single diagnostic marker for polycythaemia vera (PV). The Polycythemia Vera Study Group established diagnostic criteria more than twenty years ago. Since some new laboratory and clinical investigations have developed, these criteria can now be updated. It is proposed that the overall pattern of major and minor criteria should remain. A raised red cell mass (greater than 25% above the patient's mean normal predicted value based on surface area) and absence of a cause of secondary polycythaemia are essential criteria. Then either palpable splenomegaly or the presence of a marker of clonal haemopoiesis would support the diagnosis of PV. In the absence of both of these latter major criteria, at least two minor criteria must be present to secure the diagnosis. These are: platelet count > 400 x 10(9)/l; neutrophil count > 10 x 10(9)/l; splenomegaly demonstrated by a scanning technique; characteristic BFU-E growth or reduced serum erythropoietin value.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951778

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  12 in total

1.  Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool.

Authors:  Zbigniew Rudzki; Rafał Kawa; Krzysztof Okoñ; Ewa Szczygieł; Jerzy Stachura
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

2.  Diagnosis of polycythaemia.

Authors:  M Messinezy; T C Pearson
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

3.  Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.

Authors:  Ayako Kamiunten; Kotaro Shide; Takuro Kameda; Masafumi Ito; Masaaki Sekine; Yoko Kubuki; Tomonori Hidaka; Keiichi Akizuki; Yuki Tahira; Takanori Toyama; Noriaki Kawano; Kousuke Marutsuka; Kouichi Maeda; Masanori Takeuchi; Hiroshi Kawano; Seiichi Sato; Junzo Ishizaki; Haruko Shimoda; Kiyoshi Yamashita; Hitoshi Matsuoka; Kazuya Shimoda
Journal:  Int J Hematol       Date:  2018-07-09       Impact factor: 2.490

4.  Oxygen sensing: recent insights from idiopathic erythrocytosis.

Authors:  Frank S Lee; Melanie J Percy; Mary Frances McMullin
Journal:  Cell Cycle       Date:  2006-05-01       Impact factor: 4.534

Review 5.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

6.  The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Authors:  Zbigniew Rudzki; Tomasz Sacha; Anastazja Stój; Sylwia Czekalska; Małgorzata Wójcik; Aleksander B Skotnicki; Barbara Grabowska; Andrzej Zduńczyk; Krzysztof Okoń; Jerzy Stachura
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

7.  Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.

Authors:  A M Yesilova; S Yavuzer; H Yavuzer; M Cengiz; I D Toprak; E Hanedar; M C Ar; Z Baslar
Journal:  Int J Hematol       Date:  2016-10-03       Impact factor: 2.490

8.  Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.

Authors:  Ayako Kamiunten; Kotaro Shide; Takuro Kameda; Masaaki Sekine; Yoko Kubuki; Masafumi Ito; Takanori Toyama; Noriaki Kawano; Kousuke Marutsuka; Kouichi Maeda; Masanori Takeuchi; Hiroshi Kawano; Seiichi Sato; Junzo Ishizaki; Keiichi Akizuki; Yuki Tahira; Haruko Shimoda; Tomonori Hidaka; Kiyoshi Yamashita; Hitoshi Matsuoka; Kazuya Shimoda
Journal:  Int J Hematol       Date:  2018-02-27       Impact factor: 2.490

9.  Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD).

Authors:  Tomasz Wróbel; Grzegorz Mazur; Pawel Surowiak; Dariusz Wolowiec; Michal Jelen; Kazimierz Kuliczkowsky
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

Review 10.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.